Nature1d
Why a fortunate few don’t get ill after HIV infection
Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Temple Daily Telegram2d
Study: Kidney transplants safe between HIV patients
People with HIV can safely receive donated kidneys from deceased donors with the virus, according to a large study that comes ...
Renal & Urology News2d
HIV Preexposure Prophylaxis Use Increased in Recent Years
Generic tenofovir disoproxil fumarate/emtricitabine the most frequently prescribed medication since 2021. (HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, ...
Zacks.com on MSN3d
Gilead, MRK Report Data From Investigational Combination Study for HIV
Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...